| P50 | author | Facundo Manes | Q16301016 |
| P2093 | author name string | Michael L Miller | |
| | Stephen M Graham | |
| | Lei Xie | |
| | George T Grossberg | |
| | Ricardo F Allegri | |
| | Luis Miguel Gutiérrez-Robledo | |
| | Sergio Gloger | |
| | X Daniel Jia | |
| | Vojislav Pejović | |
| | James L Perhach | |
| P2860 | cites work | Medication non-adherence in the elderly: how big is the problem? | Q35894969 |
| | Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials | Q36478302 |
| | A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch | Q36950585 |
| | Effectiveness and safety of donepezil in Hispanic patients with Alzheimer's disease: a 12-week open-label study. | Q37199744 |
| | Caregiver Burden in Alzheimer Disease: Cross-Sectional and Longitudinal Patient Correlates | Q37678792 |
| | Performance of everyday actions in mild Alzheimer's disease. | Q38392767 |
| | A comparison of rCBF patterns during letter and semantic fluency | Q38444105 |
| | The disparate effects of Alzheimer's disease and Huntington's disease on semantic memory | Q38448534 |
| | The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia | Q39605807 |
| | The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients | Q40642214 |
| | Memantine in moderate-to-severe Alzheimer's disease | Q44388745 |
| | Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial | Q44735780 |
| | The impact of symptom severity on the cost of Alzheimer's disease. | Q46128016 |
| | Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study | Q46193667 |
| | The relation between disease severity and cost of caring for patients with Alzheimer disease in Canada | Q46251666 |
| | Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies | Q46738508 |
| | Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. | Q50912095 |
| | Relationship of behavioral and psychological symptoms to cognitive impairment and functional status in Alzheimer's disease. | Q52026890 |
| | Verbal fluency activates the left medial temporal lobe: a functional magnetic resonance imaging study. | Q52027754 |
| | Severe impairment battery. A neuropsychological test for severely demented patients. | Q52029498 |
| | Assessment of functional impairment in dementia with the Spanish version of the Activities of Daily Living Questionnaire. | Q53061759 |
| | A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. | Q53287201 |
| | Functional assessment staging (FAST) | Q57306313 |
| | [Clinical validity of two scales of instrumental activities in Alzheimer's disease] | Q81336464 |
| | Spanish version of the Bayer Activities of Daily Living scale in mild cognitive impairment and mild Alzheimer disease: discriminant and concurrent validity | Q84230371 |
| | Memantine for dementia | Q22252980 |
| | Memantine for dementia | Q24246560 |
| | “Mini-mental state” | Q25938989 |
| | Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 |
| | Adherence to Medication | Q28314923 |
| | Assessing and interpreting treatment effects in longitudinal clinical trials with missing data | Q30787487 |
| | Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies | Q30988044 |
| | Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis | Q31138894 |
| | Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials | Q31159420 |
| | Donepezil therapy in clinical practice: a randomized crossover study | Q33145215 |
| | Verbal fluency deficits co-occur with memory deficits in geriatric patients at risk for dementia: Implications for the concept of mild cognitive impairment. | Q33695984 |
| | Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers, and caregivers. | Q34390162 |
| | An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. | Q34433716 |
| | Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease | Q34561582 |
| | National estimates of the quantity and cost of informal caregiving for the elderly with dementia | Q34744409 |
| | Verbal fluency performance in dementia of the Alzheimer's type: a meta-analysis | Q35792576 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 2.5 Generic | Q19113746 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| | placebo | Q269829 |
| | placebo-controlled trial | Q108853737 |
| P304 | page(s) | 469-478 | |
| P577 | publication date | 2013-06-01 | |
| P1433 | published in | CNS Drugs | Q5013183 |
| P1476 | title | The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors | |
| P478 | volume | 27 | |